HMCLs (Human Multiple Cell Lines) :
We have developed a unique large collection of myeloma cell lines (n=40) with 20 cell lines those are dependent of the adding of exogene IL-6 for the growing and survival. These cell lines are representative of the molecular heterogeneity described in patients.
We are characterizing the response of our cell lines collection to 20 drugs including alkylating agents, proteasome inhibitors, IMiDs, corticoid, antimetabolites, NFkappaB inhibitors, CDK inhibitors, aurora kinase inhibitors, epigenetic-targeted treatments (HDACi, BRDi, HMTi…), DNA repair inhibitors and PI3-kinase inhibitors as previously described.
We also derived drug resistant myeloma cell lines (dexamethasone, bortezomib, IMiDs, melphalan, HDACi, …) to explore the development of the myeloma cells resistance of different drug.
The panel of cell lines is also representative of the heterogeneity of patients in the response to the treatment.